Nivolumab

A genetically engineered, fully humanized immunoglobulin G4 monoclonal antibody that binds to the PD-1 RECEPTOR, activating an immune response to tumor cells. It is used as monotherapy or in combination with IPILIMUMAB for the treatment of advanced malignant MELANOMA. It is also used in the treatment of advanced or recurring NON-SMALL CELL LUNG CANCER; RENAL CELL CARCINOMA; and HODGKIN'S LYMPHOMA.

Also Known As:

BMS-936558; MDX-1106; ONO-4538; Opdivo; BMS 936558; BMS936558; MDX 1106; MDX1106; ONO 4538; ONO4538

Amino Acids, Peptides, and Proteins: 1
- Proteins: 496323
  - Blood Proteins: 12679
    - Serum Globulins: 555
      - Immunoglobulins: 30911
        Antibodies: 135587
        Monoclonal Antibodies: 57170
        Humanized Monoclonal Antibodies: 220
        Nivolumab: 6492
    - Immunoproteins: 43
      - Immunoglobulins: 30911
        Antibodies: 135587
        Monoclonal Antibodies: 57170
        Humanized Monoclonal Antibodies: 220
        Nivolumab: 6492
  - Globulins: 3119
    - Serum Globulins: 555
      - Immunoglobulins: 30911
        Antibodies: 135587
        Monoclonal Antibodies: 57170
        Humanized Monoclonal Antibodies: 220
        Nivolumab: 6492

Diane Feingersh Selected Research

Diane Feingersh Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure